EyePoint, Inc.
About EyePoint, Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $31.4M
- Net income
- -$232.0M
- Total assets
- $364.0M
- Market cap
- $987.7M
- Operating margin
- -776.0%
- Net margin
- -739.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $31.4M
- Operating expenses
- $274.8M
- Operating income
- -$243.4M
- Income tax
- $279.0K
- Net income
- -$232.0M
- EPS (basic)
- $-3.17
- EPS (diluted)
- $-3.17
Balance sheet
- Total assets
- $364.0M
- Current assets
- $328.7M
- Total liabilities
- $57.9M
- Current liabilities
- $37.0M
- Shareholders’ equity
- $306.1M
Cash flow
- Operating cash flow
- -$240.1M
- Investing cash flow
- $68.6M
- Financing cash flow
- $173.6M
- Net cash flow
- $2.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $987.7M
- EPS (diluted)
- $-3.17
- Shares outstanding
- 86.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 27, 2005
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $232.0M in FY2025.
- Revenue declined 15% from FY2021 to FY2025.
- Trading 39% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review EyePoint, Inc..
Write a review
News about EyePoint, Inc.
News & sentiment via Polygon.io
